Loading…
Underlying
Underlying Price
$8.68
Type
Put
Strike
11
Expiration
May 21, 2027
DTE
213d
Moneyness
ITM
Intrinsic
$2.32
IBRX 11 Put Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Oct 23, 2026 | 3d | $2.26 | +3.67% | 5 | 18 |
| Oct 30, 2026 | 10d | — | — | 0 | 0 |
| Nov 6, 2026 | 17d | $2.05 | +18.50% | 2 | 1 |
| Nov 13, 2026 | 24d | $1.50 | +0.00% | 4 | 2 |
| Nov 20, 2026 | 31d | $2.20 | +41.03% | 7 | 394 |
| Nov 27, 2026 | 38d | — | — | 0 | 0 |
| Dec 18, 2026 | 59d | — | — | 0 | 0 |
| Jan 15, 2027 | 87d | $3.25 | +22.64% | 10 | 160 |
| Mar 19, 2027 | 150d | $3.40 | -32.00% | 4 | 5 |
| Apr 16, 2027 | 178d | — | — | 0 | 0 |
| May 21, 2027 | 213d | — | — | 0 | 0 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.